 Hoth Therapeutics Inc NASDAQ: HOTH has reported that its novel anti-cancer therapeutic demonstrated positive results in humanized mast-cell neoplasm animal models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma. The anti-cancer therapeutic, currently in development, uses mRNA frameshifting that induces apoptosis of neoplastic mast cells and cell death in neoplastic mast cells. 